Mackenzie Financial Corp Acquires 324,461 Shares of Agilent Technologies, Inc. $A

Mackenzie Financial Corp grew its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 52.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 938,670 shares of the medical research company’s stock after purchasing an additional 324,461 shares during the period. Mackenzie Financial Corp’s holdings in Agilent Technologies were worth $120,478,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in A. Brighton Jones LLC grew its position in Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after buying an additional 270 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Agilent Technologies by 15.9% in the 1st quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock valued at $602,000 after acquiring an additional 769 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Agilent Technologies by 54.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 212 shares during the period. Acadian Asset Management LLC lifted its position in shares of Agilent Technologies by 16.5% during the 1st quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock valued at $625,000 after acquiring an additional 758 shares during the period. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Agilent Technologies during the 2nd quarter worth $273,000. 87.41% of the stock is owned by institutional investors.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent agreed to acquire Biocare Medical for about $950 million — a bolt-on that strengthens its immunohistochemistry/diagnostics consumables and pathology market exposure, adding recurring reagents and slide/staining workflow products that can lift revenue durability and margin profile over time. Agilent to acquire Biocare in $950M ‘complementary combination’
• Positive Sentiment: Agilent launched “Agilent Advanced Therapeutics,” unifying its CDMO capabilities across the U.S. and Canada — a move aimed at scaling drug-development and manufacturing services that can generate higher-margin service revenue and cross-sell opportunities with instrument/consumable customers. Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
• Neutral Sentiment: Citi opened a 90‑day “upside catalyst” watch on Agilent as part of a sector sweep — this flags potential positive catalysts but is not a formal upgrade; it signals analysts are watching for near‑term drivers rather than changing the fundamental view. Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
• Neutral Sentiment: Coverage noting “steady growth amid headwinds” emphasizes Agilent’s resilient top-line and reiterated FY26 guidance but highlights macro and sector pressures that could keep near-term multiples constrained. Agilent Technologies Signals Steady Growth Amid Headwinds
• Neutral Sentiment: Analysis pieces point out Agilent has recently underperformed the S&P 500 despite analyst optimism — a reminder that valuation and sector rotation dynamics could limit near-term upside. Is Agilent Technologies Stock Underperforming the S&P 500?
• Negative Sentiment: High-profile negative commentary from Jim Cramer — saying investors “don’t need” the stock — may pressure retail sentiment and contribute to short-term volatility despite the company’s strategic moves. Jim Cramer on Agilent Technologies: “I Don’t Think You Need It”

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. UBS Group decreased their price target on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. JPMorgan Chase & Co. upped their price objective on shares of Agilent Technologies from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 25th. Morgan Stanley reduced their price objective on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Evercore raised shares of Agilent Technologies from an “in-line” rating to an “outperform” rating and raised their target price for the company from $155.00 to $160.00 in a report on Monday, January 5th. Finally, Citigroup boosted their target price on shares of Agilent Technologies from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $161.20.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $115.44 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.59 and a current ratio of 2.07. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $160.27. The stock has a market capitalization of $32.62 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 2.43 and a beta of 1.31. The stock has a fifty day moving average of $131.36 and a 200-day moving average of $135.93.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 earnings per share for the quarter, missing the consensus estimate of $1.37 by ($0.01). The business had revenue of $1.80 billion for the quarter, compared to the consensus estimate of $1.81 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.Agilent Technologies’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, sell-side analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Stockholders of record on Tuesday, March 31st will be issued a $0.255 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.9%. Agilent Technologies’s dividend payout ratio is 22.52%.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.